Compare Abeona Therapeutics Inc (ABEO) vs BHP Billiton Limited (BHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs BHP Billiton Limited — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while BHP Billiton Limited trades at $78.38 (market cap $206.17B). The key difference: BHP Billiton Limited is far larger — about 552.3× Abeona Therapeutics Inc's market cap, and BHP Billiton Limited pays a 3.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BHP | |
|---|---|---|
Market Cap | $373.32M | $206.17B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $93.15 |
52-Week Low | $4.17 | $49.36 |
Enterprise Value | $228.22M | $220.38B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BHP trades at $80.23, down 3.72% over the past 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2025 EPS of $2.12, beating expectations, but missed in Q4 2025. Recent news includes a $2.3 billion writedown at the Jansen potash project and leadership changes under incoming CEO Brandon Craig. Financials show strong profitability with an 18.97% net income margin and $20.67B in operating cash flow for 2024.
BHP's outlook is supported by robust cash flows and strategic focus on copper, but faces risks from cost overruns and labor disputes. Analyst consensus is mixed with 22.58% buy ratings. The stock presents a value opportunity with a P/E of 20.77, though investors should monitor execution on growth projects and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
